PC-005 · GLP-1 · tirzepatide
Tirzepatide
Mounjaro
Also: Zepbound
§ Overview
A dual GIP/GLP-1 receptor agonist that has shown even greater efficacy than semaglutide for weight loss and glycemic control. Tirzepatide represents the next generation of incretin-based therapies, simultaneously targeting two key metabolic pathways.
§ Mechanism
Dual agonist that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors. This dual action enhances insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite through complementary central and peripheral mechanisms.
§ Common Uses
- → Type 2 diabetes
- → Obesity/weight loss
- → Metabolic syndrome
- → Cardiovascular protection
§ Reported Side Effects
- · Nausea
- · Diarrhea
- · Decreased appetite
- · Vomiting
- · Constipation
- · Injection site reactions
§ Research, Experiences & Trends
Mechanism of Action
Dual agonist that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors. This dual action enhances insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite through complementary central and peripheral mechanisms.
Common Uses
Dosage & Pharmacology
Known Side Effects
- • Nausea
- • Diarrhea
- • Decreased appetite
- • Vomiting
- • Constipation
- • Injection site reactions